Compass Therapeutics, Inc. announced that updated results from the ongoing Phase 2 study of CTX-009 combined with paclitaxel in patients with biliary tract cancer (BTC) will be presented at a poster session of the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) taking place in San Francisco, CAJanuary 19-21, 2023. Additional poster presentations by Compass include trials in progress posters for the ongoing Phase 2/3 study of CTX-009 combined with paclitaxel in patients with biliary tract cancers (BTC) and the ongoing Phase 2 study of CTX-009 in patients with metastatic colorectal cancer (CRC).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.11 USD | -4.31% |
|
-15.27% | -28.85% |
05-28 | Compass Therapeutics Appoints Thomas Schuetz as CEO | MT |
05-28 | Compass Therapeutics, Inc. Announces CEO Changes | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.85% | 153M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- CMPX Stock
- News Compass Therapeutics, Inc.
- Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 Study of Ctx-009 in Biliary Tract Cancer at the 2023 ASCO GI Cancers Symposium